Effects of Mometasone Furoate Given Once Daily in the Evening on Lung Function and Symptom Control in Persistent Asthma
Authors:
- 1 December 2005
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (12) , 1977-1983
Abstract
BACKGROUND: The chronobiology of asthma suggests that, for once-daily dosing, an evening dose may be the most effective treatment paradigm. OBJECTIVE: To evaluate the efficacy and safety of mometasone furoate dry powder inhaler (MF-DPI) administered once daily in the evening or twice daily in patients with asthma previously maintained on twice-daily regimens of inhaled corticosteroids. METHODS: In this 12-week, multicenter, placebo-controlled trial, 268 subjects ≥12 years of age with inhaled corticosteroid–dependent asthma and baseline forced expiratory volume in 1 second (FEV 1 ) between 50% and 85% of predicted were randomized to receive treatment with MF-DPI 400 μg once daily in the evening, MF-DPI 200 μg twice daily, or placebo. The primary efficacy variable was mean change in FEV1 from baseline to endpoint. Other lung function measures, asthma symptoms, quality of life, and rescue medication use also were assessed. RESULTS: At endpoint, mean FEV 1 was significantly improved with both MF-DPI doses compared with placebo (p < 0.001). The 2 active treatment groups were statistically indistinguishable from each other. Secondary efficacy variables, including nocturnal awakenings, asthma worsenings, quality of life, and rescue medication use, were also significantly improved for both MF-DPI treatments compared with placebo. Both dosages were well tolerated; no clinically meaningful changes in laboratory values or vital signs were observed. CONCLUSIONS: MF-DPI 400 μg once daily in the evening was as effective as MF-DPI 200 μg twice daily in improving pulmonary function, asthma symptoms, and quality of life compared with placebo in subjects previously using twice-daily regimens of an inhaled corticosteroid.Keywords
This publication has 15 references indexed in Scilit:
- Once-daily inhaled corticosteroids for the treatment of asthmaCurrent Opinion in Pulmonary Medicine, 2004
- Chapters 1-3Thorax, 2003
- PrefaceJournal of Allergy and Clinical Immunology, 2002
- Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionateAnnals of Allergy, Asthma & Immunology, 2001
- Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhalerAnnals of Allergy, Asthma & Immunology, 2001
- Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthmaJournal of Allergy and Clinical Immunology, 2000
- Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthmaJournal of Allergy and Clinical Immunology, 2000
- Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthmaAnnals of Allergy, Asthma & Immunology, 2000
- Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhalerRespiratory Medicine, 1999
- Rationale for Once-Daily Therapy in AsthmaDrugs, 1999